Omnicell Q2 Earnings Call: Analyzing the Numbers and Predicting Potential Growth

August 8, 2023


Omnicell, a leading healthcare technology company, is all set to announce its second-quarter earnings results on August 1, 2023, at 4:30 PM EST. As investors eagerly await this highly anticipated event, let’s dive into the data available to gain insights into the company’s performance and future outlook. In this article, we will provide a comprehensive analysis from various perspectives, including fundamental and technical analysis, historical guidance, and analysts’ estimates. Join us on this journey as we assess Omnicell‘s potential for growth and success.

Fundamental Analysis:

ReportDate NetIncome TotalRevenue DilutedEPS unit
Q2 2023-06-30 3.5 299.0 0.08 million USD
Q1 2023-03-31 -15.0 290.6 -0.33 million USD
Q4 2022-12-31 -28.4 297.7 -0.64 million USD
Q3 2022-09-30 16.8 348.1 0.37 million USD
Q2 2022-06-30 9.1 331.4 0.20 million USD

To understand Omnicell‘s financial health and stability, it is important to analyze its past year’s financials. The company reported a Q2 net income of $3.5 million, indicating a strong turnaround from the previous quarter, where they reported a loss of $15.0 million. This positive momentum suggests a potential rebound in the company’s financials. Additionally, Omnicell‘s total revenue for Q2 stood at $299.0 million, revealing consistent growth over the past year.

Another crucial metric to consider is the Diluted EPS (earnings per share). With a positive EPS of $0.08 for Q2, Omnicell demonstrates its ability to generate profits for its shareholders. Moreover, the MorningStar consensus estimates have consistently projected an adjusted EPS of $1.13 for this quarter, reflecting the market’s confidence in the company’s performance.

Technical Analysis:

since low high change change%
1D 2023-08-04 62.0 65.3 1.1 1.7
5D 2023-07-31 61.6 65.3 1.8 2.9
1M 2023-07-06 61.6 75.1 -5.3 -7.5
3M 2023-05-08 61.6 77.1 -0.0 -0.0

Examining Omnicell‘s stock performance over the past three months can provide valuable insights for investors. The price of Omnicell shares has exhibited relative stability during this period, with a slight uptrend in recent days. The 5-day price performance showed a positive change of 2.9%, indicating growing investor interest and confidence in the company. Furthermore, the 1-month performance displayed a decrease of 7.5%, mainly attributed to market fluctuations rather than any underlying issues with Omnicell‘s operations.

Historical Guidance:

Omnicell‘s historical financial data suggests a pattern of growth and resilience. Looking back at the past year, the company’s Q3 2022 earnings report showcased a commendable net income of $16.8 million and a diluted EPS of $0.37 million. These figures highlight Omnicell‘s ability to generate consistent profits and provide a positive foundation for growth. By considering the company’s historical guidance, investors can gain valuable insights into its potential trajectory.

Analysts’ Estimates:

The MorningStar consensus estimates of $1.13 for Omnicell‘s EPS highlight the views of financial experts within the industry. For the past 90 days, analysts have maintained a steady projection, reflecting their belief in Omnicell‘s performance. Consistent estimates across various time frames indicate stability and consistency, which can instill confidence among investors and stakeholders.


As Omnicell prepares to announce its Q2 earnings results, investors should pay close attention to the fundamental and technical analysis presented. The company’s notable net income for Q2 and consistent revenue growth demonstrate its ability to adapt and thrive in the healthcare technology sector. Additionally, with positive estimates from analysts, Omnicell presents an exciting opportunity for potential growth and long-term profitability. So mark your calendars for August 1, 2023, at 4:30 PM EST and tune in to the earnings call to gain valuable insights directly from Omnicell‘s management team.

Disclaimer: The information provided in this article is purely based on available data and does not constitute financial advice. Investors should conduct further research and consult with a financial advisor before making any investment decisions.


Omnicell past year financials

– MorningStar consensus estimates

Omnicell past 3-month price performance data

Recent Posts

Leave a Comment